Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 16

1.

Sequence variants of Toll-like receptor 4 and susceptibility to prostate cancer.

Chen YC, Giovannucci E, Lazarus R, Kraft P, Ketkar S, Hunter DJ.

Cancer Res. 2005 Dec 15;65(24):11771-8.

2.

Impact of Toll-like receptor 4 polymorphisms on risk of cancer.

Kutikhin AG.

Hum Immunol. 2011 Feb;72(2):193-206. doi: 10.1016/j.humimm.2010.11.003. Epub 2010 Dec 2. Review.

PMID:
21081146
3.

Genetic determinants of the inflammatory response.

Imahara SD, O'Keefe GE.

Curr Opin Crit Care. 2004 Oct;10(5):318-24. Review.

PMID:
15385745
4.

Polymorphisms of an innate immune gene, toll-like receptor 4, and aggressive prostate cancer risk: a systematic review and meta-analysis.

Weng PH, Huang YL, Page JH, Chen JH, Xu J, Koutros S, Berndt S, Chanock S, Yeager M, Witte JS, Eeles RA, Easton DF, Neal DE, Donovan J, Hamdy FC, Muir KR, Giles G, Severi G, Smith JR, Balistreri CR, Shui IM, Chen YC.

PLoS One. 2014 Oct 31;9(10):e110569. doi: 10.1371/journal.pone.0110569. eCollection 2014. Review.

5.

Inherited genotype and prostate cancer outcomes.

Rebbeck TR.

Cancer Epidemiol Biomarkers Prev. 2002 Oct;11(10 Pt 1):945-52. Review.

6.

The TLR4 gene polymorphisms and susceptibility to cancer: a systematic review and meta-analysis.

Zhang K, Zhou B, Wang Y, Rao L, Zhang L.

Eur J Cancer. 2013 Mar;49(4):946-54. doi: 10.1016/j.ejca.2012.09.022. Epub 2012 Oct 17. Review.

PMID:
23084080
7.

[Genetic polymorphisms of susceptible genes associated with prostate cancer].

Liu Y, Xu Y.

Zhonghua Nan Ke Xue. 2010 Jul;16(7):651-5. Review. Chinese.

PMID:
20873603
8.

Genetic variants and the risk for invasive mould disease in immunocompromised hematology patients.

van der Velden WJ, Blijlevens NM, Donnelly JP.

Curr Opin Infect Dis. 2011 Dec;24(6):554-63. doi: 10.1097/QCO.0b013e32834ab1f4. Review.

PMID:
21926619
9.

Unravelling the genetics of prostate cancer.

Edwards SM, Eeles RA.

Am J Med Genet C Semin Med Genet. 2004 Aug 15;129C(1):65-73. Review.

PMID:
15264274
10.

[Advances in researches on the relationship between single nucleotide polymorphism and prostate cancer].

Wang SK, Wang ZZ, Huang YF.

Zhonghua Nan Ke Xue. 2005 Aug;11(8):605-10. Review. Chinese.

PMID:
16138582
11.

TLR4 polymorphisms and ageing: implications for the pathophysiology of age-related diseases.

Balistreri CR, Colonna-Romano G, Lio D, Candore G, Caruso C.

J Clin Immunol. 2009 Jul;29(4):406-15. doi: 10.1007/s10875-009-9297-5. Epub 2009 May 21. Review.

PMID:
19459036
12.

PTGS2-899G>C and prostate cancer risk: a population-based nested case-control study (ProtecT) and a systematic review with meta-analysis.

Murad A, Lewis SJ, Smith GD, Collin SM, Chen L, Hamdy FC, Neal DE, Donovan J, Martin RM.

Prostate Cancer Prostatic Dis. 2009;12(3):296-300. doi: 10.1038/pcan.2009.18. Epub 2009 Jun 2. Review.

PMID:
19488068
13.

The role of TLR4 896 A>G and 1196 C>T in susceptibility to infections: a review and meta-analysis of genetic association studies.

Ziakas PD, Prodromou ML, El Khoury J, Zintzaras E, Mylonakis E.

PLoS One. 2013 Nov 25;8(11):e81047. doi: 10.1371/journal.pone.0081047. eCollection 2013. Review.

14.

When is a genetic test suitable for prime time? Predicting the risk of prostate cancer as a case-example.

Li-Wan-Po A, Farndon P, Cooley C, Lithgow J.

Public Health Genomics. 2010;13(1):55-62. doi: 10.1159/000218710. Epub 2009 May 13. Review.

15.

Genetic predisposition to prostate cancer: Update and future perspectives.

Demichelis F, Stanford JL.

Urol Oncol. 2015 Feb;33(2):75-84. doi: 10.1016/j.urolonc.2014.04.021. Epub 2014 Jul 2. Review.

PMID:
24996773
16.

Prostate cancer: from the pathophysiologic implications of some genetic risk factors to translation in personalized cancer treatments.

Balistreri CR, Candore G, Lio D, Carruba G.

Cancer Gene Ther. 2014 Jan;21(1):2-11. doi: 10.1038/cgt.2013.77. Epub 2014 Jan 10. Review.

PMID:
24407349

Supplemental Content

Support Center